HIGHLIGHTS
- who: Top from the Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark have published the paper: Ultrasensitive plasma ctDNA KRAS assay for detection,, in the Journal: (JOURNAL)
- what: The authors report on the application of an ultrasensitive ctDNA KRAS assay used in patients with unresectable PDA, and its use as a prognostic biomarker independent and complementary to CA19-9. The authors report on the utilization of a novel mutant allele enrichment ctDNA assay in patients with advanced PDA yielding a circulating tumor DNA (ctDNA) KRAS baseline detection rate of 93.7 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.